A novel inhibitor stabilizes the inactive conformation of MAPK-interacting kinase 1

Yumi Matsui1, Isao Yasumatsu1, Ken Ichi Yoshida2

  • 1Daiichi Sankyo RD Novare Co. Ltd, 1-16-13 Kita-Kasai, Edogawa-ku, Tokyo 134-8630, Japan.

Insights

Mitogen-activated protein kinase (MAPK)-interacting kinases 1 and 2 (Mnk1/2) drive cancer by affecting translation initiation. A novel inhibitor stabilizes Mnk1 in its inactive form, blocking cancer cell growth.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Structural Biology

Background:

  • Mitogen-activated protein kinase (MAPK)-interacting kinases 1 and 2 (Mnk1/2) regulate translation initiation via eukaryotic translation initiation factor 4E phosphorylation.
  • Mnk1/2 activity is crucial for tumorigenesis but not essential for normal cell function, indicating therapeutic potential.

Purpose of the Study:

  • To elucidate the structural basis for Mnk1 inhibition.
  • To guide the development of novel Mnk1-targeted cancer therapies.

Main Methods:

  • Discovery of a novel Mnk1 inhibitor.
  • Determination of the crystal structure of Mnk1 in complex with the inhibitor.

Main Results:

  • The inhibitor binds to the autoinhibited state of Mnk1.
  • Stabilization of the Mnk-specific DFD motif in the DFD-out conformation.
  • Prevention of Mnk1 activation and inhibition of kinase activity.

Conclusions:

  • The identified inhibitor effectively blocks Mnk1 activity by stabilizing its autoinhibited conformation.
  • These findings offer a structural foundation for designing potent Mnk1 inhibitors for cancer treatment.

Related Concept Videos

Protein Kinases and Phosphatases02:54

Protein Kinases and Phosphatases

Proteins undergo chemical modifications that trigger changes in the charge, structure, and conformation of the proteins. Phosphorylation, acetylation, glycosylation, nitrosylation, ubiquitination, lipidation, methylation, and proteolysis are various protein modifications that regulate protein activity. Such modifications are usually enzyme-driven.
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
15.2K
Conformity01:20

Conformity

Conformity is the change in a person’s behavior to go along with the group, even if that person does not agree with the group.
48.2K
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
8.6K
Eukaryotic Transcription Inhibitors01:52

Eukaryotic Transcription Inhibitors

Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
11.1K
Nuclear Stability03:18

Nuclear Stability

Protons and neutrons, collectively called nucleons, are packed together tightly in a nucleus. With a radius of about 10−15 meters, a nucleus is quite small compared to the radius of the entire atom, which is about 10−10 meters. Nuclei are extremely dense compared to bulk matter, averaging 1.8 × 1014 grams per cubic centimeter. If the earth’s density were equal to the average nuclear density, the earth’s radius would be only about 200 meters.
To hold positively charged protons together...
23.4K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
561